Monoclonal gammopathy of cutaneous significance

Affiliations

¹ Department of Dermatology, Chelsea and Westminster Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
² Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.

Comment

Khawar Hussain et al. Clin Exp Dermatol. 2022 Apr.

. 2022 Apr;47(4):778.

doi: 10.1111/ced.15062. Epub 2021 Dec 30.

¹ Department of Dermatology, Chelsea and Westminster Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
² Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.

No abstract available

Comment on

Thalidomide for necrobiotic xanthogranuloma.
Ali FR, Lear JT. Ali FR, et al. Clin Exp Dermatol. 2022 Apr;47(4):769-770. doi: 10.1111/ced.15047. Epub 2021 Dec 29. Clin Exp Dermatol. 2022. PMID: 34856016 No abstract available.

1. Ali F, Lear J. Thalidomide for necrobiotic xanthogranuloma. Clin Exp Dermatol 2021. https://doi.org/10.1111/ced.15047
1. Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Dermatol 2021. https://doi.org/10.1111/ced.15019
1. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
1. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
1. Rajkumar SV, Dispenzieri A, Fonseca R et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-6.